Antifungal Antibiotics and Breakthrough Bacteremias | Zendy

Richard P. Wenzel | Zendy; Chris Gennings | Zendy; Michael B. Edmond | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Antifungal Antibiotics and Breakthrough Bacteremias

Author(s) -

Richard P. Wenzel,

Chris Gennings,

Michael B. Edmond

Publication year - 2001

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1086/320534

Subject(s) - medicine , cefepime , meropenem , neutropenia , bacteremia , ceftazidime , vancomycin , imipenem , antibiotics , absolute neutrophil count , aminoglycoside , intensive care medicine , microbiology and biotechnology , chemotherapy , antibiotic resistance , staphylococcus aureus , biology , bacteria , genetics , pseudomonas aeruginosa

Patients with fever and neutropenia are at high risk for infection ( approximately 50%) and bacteremia ( approximately 20%). As a result, most are treated with antibacterial prophylaxis until their absolute neutrophil count exceeds 500 cells/mm(3) and their temperature returns to normal. The 1997 guidelines of the Infectious Diseases Society of America suggested 1 of 3 regimens: vancomycin plus ceftazidime, monotherapy with ceftazidime or imipenem (possibly cefepime or meropenem), or dual therapy with an aminoglycoside plus an antipseudomonal beta-lactam.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research